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dictive values, but age and CRP remained powerful indepen-Inflammation enhances cardiovascular risk and mortality in
dent predictors of both overall death and cardiovascular death.hemodialysis patients.
Conclusion. These results suggest that a considerable num-Background. Atherosclerosis, a major problem in patients
ber of hemodialysis patients exhibit an activated acute phaseon chronic hemodialysis, has been characterized as an inflam-
response, which is closely related to high levels of atherogenicmatory disease. C-reactive protein (CRP), the prototypical
acute phase protein in humans, is a predictor of cardiovascular vascular risk factors and cardiovascular death. The mechanisms
mortality in the general population. We hypothesize that sev- of activated acute phase reaction in patients on chronic hemodi-
eral of the classic, as well as nontraditional, cardiovascular risk alysis remain to be identified. A successful treatment of the
factors may respond to acute phase reactions. An activated inflammatory condition may improve long-term survival in
acute phase response may influence or predict cardiovascular these patients.
risk.
Methods. In 280 stable hemodialysis patients, serum lipids,
apolipoproteins (apo) A-I and B, lipoprotein(a) [Lp(a)], fi-
Atherosclerotic vascular disease is the most frequentbrinogen, and serum albumin (Salb) were determined in relation
to CRP and serum amyloid A (SAA), two sensitive markers complication in patients undergoing chronic hemodialy-
of an acute phase response. Mortality was monitored prospec- sis treatment. Cardiovascular disease is the major cause
tively over a two year period. of mortality, accounting for approximately half of all
Results. Serum CRP and SAA were found to be elevated
deaths in this population. Prominent risk factors known(more than 8 and more than 10 mg/liter, respectively) in 46%
to increase the incidence of atherosclerotic vascular dis-and 47% of the patients in the absence of clinically apparent
infection. Patients with elevated CRP or SAA had significantly ease are various disorders of lipoprotein metabolism,
higher serum levels of Lp(a), higher plasma fibrinogen, and including high serum lipoprotein(a) [Lp(a)], possibly
lower serum levels of high-density lipoprotein cholesterol, apo homocysteine, and disorders of the hemostatic system.A-I, and Salb than patients with normal CRP or SAA. The rise
The main metabolic abnormality of the lipoprotein pro-in Lp(a) concentration was restricted to patients exhibiting
file is a delayed catabolism of triglyceride-rich apolipo-high molecular weight apo(a) isoforms. During follow-up, 72
patients (25.7%) had died, mostly due to cardiovascular events protein B (apo B)-containing lipoproteins caused by a
(58%). Overall mortality and cardiovascular mortality were decreased activity of lipolytic enzymes, hypertriglyceri-
significantly higher in patients with elevated CRP (31% vs.
demia, and a decrease in high-density lipoprotein choles-16%, P , 0.0001, and 23% vs. 5%, P , 0.0001, respectively)
terol (HDL-C), apo A-I, and apo A-II [1, 2].or SAA (29% vs. 19%, P 5 0.004, and 20 vs. 10%, P 5 0.008,
respectively) and were also higher in patients with Salb of lower Lipoprotein(a), a known risk factor of premature ath-
than 40 g/liter (44% vs. 14%, P , 0.0001, and 34% vs. 6%, erosclerosis [3, 4], was found to be consistently elevated
P , 0.0001, respectively). Univariate Cox regression analysis in patients with end-stage renal disease (ESRD) [5–8].demonstrated that age, diabetes, pre-existing cardiovascular
Plasma concentrations of Lp(a) are highly heritable anddisease, body mass index, CRP, SAA, Salb, fibrinogen, apo A-I,
mainly determined by a size polymorphism of apo(a).and Lp(a) were significantly associated with the risk of all-cause
and cardiovascular mortality. During multivariate regression The molecular mass of apo(a) is inversely related to
analysis, SAA, fibrinogen, apo A-I, and Lp(a) lost their pre- Lp(a) concentrations. In patients with ESRD, however,
elevation of Lp(a) is not only related to size polymor-
phism of apo(a) [7]. Lp(a) has been shown to have theKey words: acute phase response, lipids, apolipoprotein, lipoprotein(a),
albumin, fibrinogen, C-reactive protein, mortality, atherosclerosis. characteristics of an acute phase reactant [9]. Two recent
studies have demonstrated an inverse correlation be-
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the role of hemostatic factors in the pathogenesis of on stable hemodialysis treatment for 55 6 56 months
atherosclerosis. Several studies have reported a positive (range from 1 to 276 months) concurrently entered the
and independent association between plasma fibrinogen study. Dialysis was performed three times a week for
and cardiovascular mortality in the general population 12.3 6 1.5 hr/week (range from 6 to 16 hr/week). End-
[11]. Recent studies demonstrated that fibrinogen is stage renal failure was due to glomerulonephritis in 88
markedly increased in hemodialysis patients, especially patients (32%), diabetes mellitus in 63 (22%), small kid-
in those suffering from diabetes mellitus [12–15]. neys of unknown origin in 44 (16%), interstitial nephritis
Similar changes in plasma lipids, Lp(a), apolipoprot- in 36 (13%), hereditary kidney disease in 29 (10%), vas-
eins, and fibrinogen were found in patients with acute cular renal disease in 11 (4%), bilateral nephrectomy in
infection [16], severe trauma, and myocardial infarction 5 (2%), and plasmocytoma in 4 patients (1%). Eighty-one
[9, 17], indicating that an inflammatory condition may patients (29%) suffered from diabetes mellitus (74 non–
be responsible, at least in part, for the alterations in insulin-dependent diabetes mellitus, 7 insulin-dependent
lipoprotein metabolism and fibrinogen in patients on diabetes mellitus) at the time of sampling. Hemodialysis
chronic hemodialysis. treatment was performed using conventional bicarbonate-
In a prospective study, high serum levels of C-reactive buffered dialysate in all patients. Dialyzer membranes
protein (CRP) could be identified as a prominent risk
used were made of cuprophane (2%), hemophane (36%),
factor for cardiovascular events in apparently healthy
polysulfone (50%), polyamide (11%), and poly-methyl-men [18]. Baseline plasma CRP concentrations were
metacrylate (1%). Medication of patients included: anti-higher in men who went on to have myocardial infarction
hypertensive drugs (60%); calcium carbonate and/or alu-or stroke than among men without vascular events dur-
minum hydroxide; vitamin B, C, and D supplementation;ing a follow-up period exceeding eight years. The use of
epoietin; iron gluconate; aspirin (41%); and lipid-loweringaspirin, an anti-inflammatory agent, significantly reduced
agents (17%). One hundred and sixty middle-aged healthythe risk of myocardial infarction among those in the
persons served as controls (71 women, 89 men; meanhighest quartile of CRP elevation [18]. Recently, Bergs-
age 50.2 6 0.6 years, age range from 40 to 67 years).tro¨m et al reported that in patients with ESRD, elevated
The study was carried out according to the principlesconcentration of CRP was the most powerful predictor
of the Declaration of Helsinki. All patients gave theirof death during one year. When albumin levels were
informed consent before entering the study, and the pro-statistically corrected for CRP, they lost their value in
tocol for this study was approved by the appropriatepredicting death [19].
institutional review board.We therefore hypothesize that an activated acute
phase response is responsible for the atherogenic condi-
Baseline examinationtion in hemodialysis patients and may, in part, explain
the high incidence of cardiovascular complications. The Patients were interviewed and examined at baseline.
purpose of this study was to explore in a large group Weight and height were determined, and body mass in-
of patients on chronic hemodialysis treatment whether dex (BMI; kg/m2) was calculated. Angina, possible myo-
atherogenic changes in plasma lipids, Lp(a), and fibrin- cardial infarction, cerebrovascular events, and intermit-
ogen are influenced by an activated acute phase reaction. tent claudication were assessed by questionnaire and by
A further objective was to determine predictors of over- appropriate technical diagnostics. Additional informa-
all and cardiovascular mortality in hemodialysis patients, tion was obtained from the general practitioners and the
considering particularly the changes in plasma lipids, physicians in the outpatient dialysis centers. Smoking
Lp(a), fibrinogen, and the acute phase reactants CRP habits and the presence of diabetes were recorded.
and serum amyloid A (SAA).
Follow-up study
METHODS A follow-up investigation was performed prospec-
tively at 12 and 24 months after the baseline examination.Study population
Data of all 280 hemodialysis patients from the originalBetween September and November 1995, 303 white
cohort could be obtained for analysis of two-year mortal-patients on chronic hemodialysis treatment from the di-
ity. Date and cause of death were evaluated from recordsalysis unit of the University Clinic of Wu¨rzburg and from
and from interviews with the physicians in the outpatientthree other outpatient dialysis centers were screened for
dialysis centers. Causes of death were classified as mor-the study. Twenty-three patients hospitalized during the
tality caused by cardiovascular events (myocardial in-screening period or exhibiting clinical signs of overt in-
farction, congestive heart failure, sudden death, andfections were not included in the study. Therefore, a
stroke) and noncardiovascular events (infection, neo-total of 280 patients (130 women and 150 men, mean
age 62.4 6 13.7 years, age range from 20 to 88 years) plasma, unknown causes).
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Sampling procedure and laboratory analysis Mann–Whitney’s U test for non-normally distributed
variables. Differences between more than two groupsBlood samples were collected on ice (48C) prior to
were assessed using the H-test according to Kruskal andinitiation of the hemodialysis session and prior to heparin
Wallis. Bivariate regression and correlation analysesadministration, and were centrifuged within 60 minutes
were performed between all available data by using theafter collection. Measurements of lipids, apolipopro-
Spearman rank method. The cumulative incidence ofteins, Lp(a), fibrinogen, albumin, and CRP were per-
death during follow-up was estimated by the Kaplan-formed on fresh samples. Serum samples for measure-
Meier method. To compare the differences of variablesment of SAA and determination of apo(a) isoform were
that influence the survival estimated functions betweenstored at 2708C. Fibrinogen was measured by the throm-
two groups, the log-rank test was used. Relative risk ofbin time method (Clauss) in a blood sample anticoagu-
mortality for different parameters was estimated usinglated with 3.8% sodium citrate. Total cholesterol and
the Cox proportional hazards model. Variables that sig-triglycerides were measured by enzymatic colorimetric
nificantly influenced all-cause and cardiovascular mortal-methods (cholesterol CHOD-PAP, triglycerides PAP;
ity in univariate analyses (P , 0.05) were included in aBoehringer Mannheim, Mannheim, Germany). HDL-C
multivariate Cox regression analysis. Relative risks andwas measured after precipitation with MgCl2, and low-
density lipoprotein cholesterol (LDL-C) was calculated their 95% confidence intervals were calculated with the
using the Friedewald formula (in patients with triglycer- use of the estimated regression coefficients and their
ides of less than 400 mg/dl). Apo B and apo A-I were standard errors in the Cox regression analysis. In addi-
measured by nephelometric methods. Measurement of tion, chi-square statistics were given. Data are expressed
serum albumin (Salb) was carried out on serum using the as mean 6 sd. P values of less than 0.05 were considered
bromocresol green method. The serum concentration of significant. Data analysis was performed using the SPSS/
CRP was measured by a nephelometric immunoassay PC1 package (SPSS Inc., Chicago, IL, USA).
(NA Latex CRP Reagent; Behring Institute, Marburg,
Germany). SAA was analyzed by an enzyme-linked im-
RESULTSmunosorbent assay (Hemagen Kit; Hemagen Diagnos-
Clinical and biochemical characteristics oftics Inc., Waltham, MA, USA). The normal range for
CRP is less than 8 mg/liter, and the range for SAA in hemodialysis patients and healthy controls
normal subjects is between 1 and 10 mg/liter [20]. Lp(a) Table 1 shows the clinical and biochemical characteris-
serum concentrations were determined by a nephelomet- tics of hemodialysis patients and healthy controls. In 81
ric immunoassay (Immuno, Vienna, Austria). patients, diabetes mellitus was a comorbid condition.
Diabetic patients were on hemodialysis treatment for aApo(a) isotyping
shorter duration of time but were affected more often
Apoprotein(a) isoform determination was carried out by coronary artery disease and intermittent claudication
on serum using a sensitive immunoblotting technique than nondiabetics. Hemodialysis patients had higher se-
with modifications [21]. Briefly, serum samples were sol- rum triglycerides, cholesterol, LDL-C, and apo B and
ubilized in a solution containing 75% glycerol, 0.5% bro- had reduced HDL-C and apo A-I than healthy controls.
mophenol blue, 10% sodium dodecyl sulfate, and mer-
Lp(a) serum concentration was found to be elevatedcaptoethanol, were denatured at 958C for 10 minutes,
(more than 30 mg/dl) in 23% of hemodialysis patientsand were applied to 4% sodium dodecyl sulfate-PAGE.
and in 12% of healthy controls. Therefore, Lp(a) meanGels were run for approximately two hours at 125/40
and median values were significantly higher in hemodial-mA. After transfer of the proteins to a nitrocellulose
ysis patients than in controls (mean 6 sd, 25.5 6 34.9transfer membrane (NOVEX, San Diego, CA, USA),
vs. 16.3 6 23.5 mg/dl; median, 13.6 vs. 9.2 mg/dL, P ,incubation of the membranes with antibodies was per-
0.05). Apo(a) isoform frequency distribution (HMW/fomed using an Lp(a) phenotyping kit purchased from
LMW phenotypes) did not differ between hemodialysisImmuno (Vienna, Austria) containing anti-Lp(a) mono-
patients and healthy controls. However, this rise of serumclonal antibodies for detection. A standard of a defined
Lp(a) levels was restricted to patients exhibiting HMWisoform pool (B, S1, S3, S4) was used on each gel. Most
isoforms (mean 6 sd, 22.2 6 32.5 vs. 11.4 6 13.2 mg/dl;patients showed staining of two apo(a) bands. The low
median, 14 vs. 8 mg/dl, P , 0.05). In patients with LMWmolecular weight (LMW) group includes all subjects with
isoforms, serum Lp(a) levels did not differ significantlyat least one of the isoforms B, S1, or S2. The high molecu-
from healthy controls (mean 6 sd, 50.7 6 42.8 vs. 42.2 6lar weight (HMW) group comprises all subjects with only
51.5 mg/dl; median, 43 vs. 37 mg/dl, respectively). Athe S3 or S4 isoforms or with a null type.
considerable proportion of patients (64%) exhibited ele-
Statistical analysis vated plasma fibrinogen levels (more than 3.50 g/liter).
Therefore, mean values in patients were significantlyComparison between two groups was performed using
Student’s t-test for normally distributed variables and higher than in controls. Serum concentration of CRP
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Table 1. Characteristics of hemodialysis patients and controls
All patients Non–diabetics Diabetics Controls
Characteristics (N 5 280) (N 5 199) (N 5 81) (N 5 160)
Age, years 62.4613.7 60.7614.5 66.5610.7 50.2 67.6f
range 20–88 20–88 30–85 40–67
Gender, male/female 150/130 105/94 45/36 89/71
Months on hemodialysis 54.6 655.9 63.6660.9 32.3 631.6c —
Length of dialysis hours/week 12.361.5 12.361.5 12.461.5 —
BMI kg/m2 23.464.2 23.364.2 23.464.3 26.4 63.5e
Smoking % 20.1 20.4 19.4 17.9
Coronary artery disease % 19 15 28a 0
Intermittent claudication % 12 5 31c 0
Cerebrovascular disease % 13 10 19 0
C-reactive protein mg/liter* 16.2 624.5 12.9617.2 24.4635.5a 2.262.4f
Serum amyloid A mg/liter** 17.4627.3 13.4612.1 27.1645.7a nd
Serum albumin g/liter 42.764.0 43.263.8 41.4 64.2c 46.162.4f
Fibrinogen g/liter 4.1661.24 4.0361.17 4.4761.34a 2.8260.56f
Apolipoprotein B mg/dl 127.4640.4 125.9638.2 131.2645.3 103.9 622.9f
Apolipoprotein A-1 mg/dl 138.0628.9 140.2626.8 132.6633.3a 165.7624.6f
Cholesterol mg/dl 201.9646.6 201.4644.4 203.2652.0 191.2 631.3e
Triglycerides mg/dl 230.36144.9 222.66140.2 249.36155.2 172.2 6122.6f
LDL colesterol mg/dl 114.9640.9 115.8639.9 112.6644.0 101.2 626.9f
HDL cholesterol mg/dl 43.4617.6 44.4616.5 40.8 620.0b 57.4613.9f
Lipoprotein(a) mg/dl 25.5634.9 25.4636.1 25.9632.2 16.3623.5d
[13.6] [13.3] [14.8] [9.2]
Data are given as mean 6 sd. Median values for Lp(a) are given in parentheses. Serum for measurement was available only in * 278 or ** 238 hemodialysis
patients. Statistically significant differences between non-diabetic and diabetic hemodialysis patients are marked a P , 0.05, b P , 0.01, c P , 0.001 and between
hemodialysis patients and controls are marked d P , 0.05, e P , 0.01, f P , 0.001. Abbreviations are: nd, not done; BMI, body mass index; LDL, low density
lipoprotein; HDL, high density lipoprotein.
was significantly lower, and Salb was significantly higher to those patients with values in the normal range (Table
3). This elevation of Lp(a) correlated with high serumin controls compared with hemodialysis patients.
C-reactive protein, SAA, and fibrinogen were found levels of SAA and CRP and was restricted to patients
exhibiting HMW apo(a) isoforms (Fig. 2). In addition,to be significantly higher, and Salb, HDL-C, and apo A-I
were significantly lower in diabetic than in nondiabetic Salb, apo A-I, and HDL-C levels were significantly lower
in hemodialysis patients with elevated SAA, as well ashemodialysis patients. No differences were found in apo
B, cholesterol, triglycerides, and LDL-C. No difference in patients with elevated CRP serum concentrations (Ta-
ble 3). No significant differences were detected in trigly-in blood levels of lipids, apoproteins, Lp(a), fibrinogen,
Salb, CRP, and SAA levels were detected when mem- cerides, total cholesterol, LDL-C, and apo B between
the two groups of hemodialysis patients (Table 3). Meanbrane material of the various dialyzers was analyzed.
age was higher in hemodialysis patients with high CRP
Effect of acute phase on plasma lipids, apoproteins, or high SAA levels than in patients with low CRP or
Lp(a), fibrinogen, and serum albumin in low SAA levels (mean 6 sd, 65.3 6 12.2 vs. 61.1 6 14.4,
hemodialysis patients P 5 0.04, and 66.2 6 11.5 vs. 60.0 6 14.7 years, P 5 0.02,
respectively). Age significantly correlated with serumThe distributions of serum concentrations of the acute
levels of CRP and Salb but not with levels of SAA (Table 2).phase markers CRP and SAA are given in Figure 1.
CRP concentrations were found to be elevated (more
Analysis of two-year mortality ratethan 8 mg/liter) in 46%, and SAA concentrations (more
than 10 mg/liter) were elevated in 47% of patients. In During the follow-up period of two years, 72 out of
280 patients (25.7%) had died, most from cardiovascular18% of patients, Salb was lower than 40 g/liter, and in
3% of patients, it was lower than 35 g/liter. Both CRP events (42 out of 72, 58%), for example, myocardial
infarction (19%, N 5 14), congestive heart failure (18%,and SAA concentrations were negatively correlated with
Salb (r 5 20.37, P , 0.0001, and r 5 2 0.31, P , 0.0001, N 5 13), sudden death (15%, N 5 11), or stroke (6%,
N 5 4). Noncardiac causes of death were septicemiarespectively; Table 2).
When subdividing the patients into groups with low (18%, N 5 13), neoplasma (11%, N 5 8), or other un-
known causes (13%, N 5 9). During follow-up, all-cause,or high CRP (less than or more than 8 mg/liter) or SAA
serum levels (less than or more than 10 mg/liter), plasma as well as cardiovascular mortality, was significantly
higher in patients with elevated CRP (31% vs. 16%, P ,fibrinogen and serum Lp(a) values were significantly
higher in patients exhibiting elevated CRP or SAA than 0.0001, and 23% vs. 5%, P , 0.0001, respectively) or
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Fig. 1. Frequency distribution of (A) C-reactive protein (CRP) and (B) serum amyloid A (SAA) in patients with end-stage renal disease treated
with hemodialysis. Six percent of the patients exhibiting CRP levels between 70 and 152 mg/liter were not depicted. Symbols are: (h) normal
value; (j) out of the normal range.
Table 2. Spearman rank correlation matrix for 16 variables
Variable Diab Age Sex BMI Smo Salb Fib Chol TG LDL-C HDL-C ApoB ApoA-I Lp(a) CRP SAA
Age 0.19b
Sex 20.02 0.00
BMI 0.01 20.02 20.09
Smo 20.11 20.19b 20.20b 20.03
Salb 20.19b 20.13b 20.14a 0.12a 0.07
Fib 0.16b 0.17b 20.03 0.17b 0.01 20.22c
Chol 0.01 0.09 0.27c 0.18b 20.13a 0.12a 0.17b
TG 0.08 0.03 20.03 0.26c 0.09 0.12a 0.15a 0.39c
LDL-C 20.03 0.07 0.25c 0.15a 20.22b 0.02 0.14a 0.90c 0.14a
HDL-C 20.09 0.03 0.21c 20.22c 20.01 0.06 20.10 0.10 20.43c 20.05
ApoB 0.06 0.11a 0.11 0.29c 20.06 0.16b 0.20b 0.79c 0.78c 0.74c 20.34c
ApoA-I 20.12a 20.07 0.23c 20.06 0.04 0.16b 20.11 0.21c 20.19b 0.06 0.72c 20.16b
Lp(a) 0.00 0.08 0.14a 20.02 20.06 20.13a 0.01 0.21c 20.18b 0.28c 0.16b 0.04 0.01
CRP 0.13a 0.17b 20.20c 0.05 0.00 20.37c 0.48c 20.11 20.01 20.07 20.21c 20.02 20.31c 0.14a
SAA 0.23c 0.02 20.10 0.04 0.05 20.31c 0.40c 20.01 0.02 0.03 20.12 0.04 20.28c 0.18b 0.73c
CVD 0.32b 0.22b 20.26b 20.22 20.05 20.38 0.09 20.01 0.09 0.00 20.15 0.08 20.24b 0.21 0.18b 0.11
Abbreviations are given in the Appendix.
a P , 0.05, b P , 0.01, c P , 0.001
SAA (29% vs. 19%, P 5 0.004, and 20% vs. 10%, P 5 cardiovascular mortality were found with increasing
quartiles of baseline SAA values and with decreasing0.008, respectively) and were also higher in patients with
Salb lower than 40.0 g/liter (44% vs. 14%, P , 0.0001, quartiles of Salb (Table 4). By univariate Cox regression
analysis, various factors were significantly associatedand 34% vs. 6%, P , 0.0001, respectively) than in pa-
tients with CRP, SAA, and Salb in the normal range. The with all-cause as well as cardiovascular mortality (Table
5): age, male sex, presence of diabetes, pre-existing car-relative risk of death in general as well as death caused
by cardiovascular events increased significantly with each diovascular disease, BMI, CRP, SAA, Salb, fibrinogen,
apo A-I, and serum Lp(a). The multivariate stepwisequartile of baseline concentration of CRP (Fig. 3 and
Table 4). Patients in the highest quartile (more than 15.8 Cox regression analyses demonstrated that age, BMI,
CRP, presence of diabetes, low Salb, and pre-existing car-mg/liter) had a 4.6-fold higher risk for all-cause and a
5.5-fold higher risk for cardiovascular mortality during diovascular disease were independent predictors of all-
cause mortality. Cardiovascular mortality was only de-follow-up than those in the lowest quartile (less than
3.3 mg/liter). Similar trends for the risks of overall and pendent of age, CRP, BMI, presence of diabetes, and
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Table 3. Fibrinogen, albumin, lipids, and lipoproteins in hemodialysis patients with low and elevated serum levels of
serum amyloid A (SAA) and C-reactive protein (CRP)
Hemodialysis patients
SAA , 10 mg/liter SAA . 10 mg/liter CRP , 8 mg/liter CRP . 8 mg/liter Healthy controls
N 5 123 (52%) N 5 115 (48%) N 5 146 (53%) N 5 132 (47%) N 5 160
Fibrinogen g/liter 3.74 6 1.12 4.57 6 1.27c 3.60 6 0.9 4.77 6 1.2c 2.82 6 0.56
Albumin g/liter 43.7 6 3.5 41.9 6 3.9c 43.8 6 3.5 41.4 6 4.3c 46.1 6 2.4
Lp(a) mg/dl 20.6 6 25.2 [13] 33.4 6 44.7b [18] 22.6 6 31.9 [12] 28.7 6 38.2a [16] 16.3 6 23.5 [9]
ApoB mg/dl 123.9 6 36.9 133.7 6 42.5 126.6 6 40.3 128.7 6 40.7 103.9 6 22.9
ApoA-1 mg/dl 143.9 6 29.1 129.9 6 26.3c 146.2 6 28.0 128.9 6 27.3c 165.7 6 24.6
Triglycerides mg/dl 215.0 6 134.0 244.6 6 155.6 225.1 6 139.5 237.6 6 151.5 172.2 6 122.6
Cholesterol mg/dl 203.0 6 46.3 204.3 6 46.6 206.7 6 48.2 196.8 6 44.8 191.2 6 31.3
LDL-C mg/dl 115.2 6 43.7 115.9 6 37.6 118.1 6 44.9 111.4 6 36.4 101.2 6 26.9
HDL-C mg/dl 47.0 6 19.2 41.9 6 15.4a 47.1 6 19.2 39.2 6 14.8c 57.4 6 13.9
Data are given as mean 6 sd. Median values for Lp(a) are given in parentheses. Serum for measurement of SAA and CRP was not available in all 280 hemodialysis
patients.
a P , 0.05, b P , 0.01, c P , 0.001
Fig. 2. Serum levels of Lp(a) in hemodialysis patients (HD) with elevated (A) CRP (more than 8 mg/liter) and elevated (B) SAA (more than
10 mg/liter) compared with patients with CRP and SAA in the normal range and healthy controls. In (A) symbols are: (h) healthy controls; ( )
HD with CRP , 8 mg/liter; ( ) HD with CRP . 8 mg/liter. In (B) symbols are: (h) healthy controls; ( ) HD with SAA , 10 mg/liter; ( )
HD with SAA . 10 mg/liter. Data are given as mean 6 sem. Abbreviations are: LMW, patients with low-molecular weight apo(a) isoforms (B,
S1, S2); HMW, patients with high-molecular weight apo(a) isoforms (S3, S4, . S4). 1P , 0.05; 1 1P , 0.01; 1 1 1P , 0.001 (vs. HD without
activated acute phase). *P , 0.05; **P , 0.01; ***P , 0.001 (vs. healthy controls).
male sex. Salb was not significantly associated with the main finding was that a considerable proportion of pa-
tients (approximately 50%) exhibited an activated acuterisk of cardiovascular death in the multivariate model
phase response, characterized by an increase of CRP and(Table 6). However, excluding CRP and SAA from the
SAA. These prototypical acute phase proteins were asso-multivariate analysis, Salb was closely associated with the
ciated with an increase of the atherogenic plasma proteinsrisk of all-cause (x2 5 16.7, RR 5 0.26, P , 0.0001) as
Lp(a) and fibrinogen. The antiatherogenic HDL-C andwell as cardiovascular death (x2 5 12.7, RR 5 0.20, P 5
its main structural protein component apo A-I were neg-0.0004) during follow-up. Fibrinogen, SAA, apo A-I, and
atively correlated with CRP and SAA. During a two-yearserum Lp(a) lost their significance as survival factors in
prospective follow-up, an activated acute phase process,the multivariate Cox model for both overall and cardio-
as represented by elevated levels of CRP, was identifiedvascular mortality.
to be a strong independent predictor of overall and car-
diovascular mortality in hemodialysis patients, besides
DISCUSSION age, low BMI, presence of diabetes, pre-existing cardio-
This study shows that inflammation is associated with vascular disease, and male gender.
an enhanced cardiovascular risk profile and an increased Numerous studies have shown that hypoalbuminemia
predicts death in hemodialysis patients. Malnutrition hascardiovascular mortality in hemodialysis patients. The
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Fig. 3. Kaplan-Meier estimates of survival during follow-up with regard to all-cause (A) and cardiovascular mortality (B) in relation to quartiles
of serum concentrations of CRP.
Table 4. Relative risks of 2-year mortality according to quartiles of baseline serum concentrations of C-reactive protein,
serum amyloid A and albumin
All-cause mortality Cardiovascular mortality
Relative risk Relative risk
Risk factor (95% CI) P value (95% CI) P value
C-reactive protein mg/liter
, 3.3 1 1
3.3–7.4 1.66 (0.68–4.00) 0.26 0.65 (0.16–2.74) 0.56
7.5–15.7 2.77 (1.22–6.30) 0.01 2.91 (1.04–8.16) 0.04
. 15.7 4.64 (2.13–10.15) , 0.0001 5.48 (2.06–14.54) , 0.0001
Serum amyloid A mg/liter
, 7.1 1 1
7.2–9.8 0.80 (0.32–2.04) 0.65 0.43 (0.11–1.67) 0.22
9.9–15.8 1.68 (0.76–3.71) 0.19 1.57 (0.60–4.14) 0.35
. 15.8 2.87 (1.37–6.01) 0.005 2.65 (1.0–6.59) 0.03
Albumin g/liter
, 41.0 1 1
41.1–43.0 0.38 (0.19–0.78) 0.008 0.40 (0.17–0.94) 0.03
43.1–45.0 0.39 (0.21–0.72) 0.002 0.23 (0.09–0.56) 0.001
. 45.0 0.21 (0.11–0.40) , 0.0001 0.16 (0.07–0.39) , 0.001
been attributed to the low levels of albumin in ESRD ate Cox regression analysis, low Salb was correlated to
the same magnitude as high CRP and high age withpatients [22]. The terms hypoalbuminemia and malnutri-
tion are usually used interchangeably in these patients. an increased overall as well as cardiovascular mortality
during follow-up. However, in the multivariate Cox re-Recently, Kaysen et al [23] and Qureshi et al [24] have
convincingly demonstrated that activity of the acute gression analysis, Salb lost its significance as an indepen-
dent risk factor for cardiovascular death, and the re-phase response is an important predictor of low Salb in
hemodialysis patients independently of nutritional fac- maining predictive value for all-cause mortality was
much lower than in the univariate analysis. However,tors. Most of our patients exhibited Salb levels in a range
that normally predicts low value for mortality. Only 18% if CRP was not taken into account in the multivariate
analysis, Salb remained, after age, the strongest predictorof patients had Salb levels lower than 40, and 3% had
levels lower than 35 g/liter. Nevertheless, in the univari- for both overall and cardiovascular mortality. Despite
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Table 5. Predictors of 2-year mortality in hemodialysis patients in the univariate Cox regression analysis
All-cause mortality Cardiovascular mortality
Variable Units x2 Relative risk P x2 Relative risk P
Age Years 20.51 1.05 ,0.0001 22.43 1.08 ,0.0001
Gender Ref 5 male 2.75 0.66 0.09 5.95 0.41 0.01
Diabetes Ref 5 nondiabetic 18.99 2.82 ,0.0001 13.64 3.12 0.0002
BMI kg/m2 9.96 0.90 0.002 5.42 0.90 0.02
Duration on dialysis Months 1.41 0.99 0.23 0.43 0.99 0.51
Smoking Ref 5 non smoking 0.34 1.18 0.55 0.09 1.12 0.76
Pre-existing CVD Ref 5 no CVD 21.45 3.04 ,0.0001 15.23 3.41 0.0001
C-reactive protein mg/liter 23.40 1.16 ,0.0001 27.81 1.21 ,0.0001
Serum amyloid A mg/liter 10.92 1.00 0.001 10.56 1.01 0.001
Serum albumin g/liter 23.95 0.36 ,0.0001 22.67 0.31 ,0.0001
Fibrinogen g/liter 6.59 1.27 0.01 11.27 1.50 0.0008
Cholesterol mg/dl 3.55 0.99 0.06 1.74 0.99 0.12
Triglyceride mg/dl 2.90 0.99 0.08 2.10 0.99 0.14
LDL cholesterol mg/dl 1.95 0.99 0.16 0.54 0.99 0.46
HDL cholesterol mg/dl 0.00 1.00 0.97 0.05 0.99 0.81
Lipoprotein(a) mg/dl 4.18 1.00 0.04 3.07 1.00 0.07
Apolipoprotein A-I mg/dl 12.80 0.98 0.0003 7.43 0.98 0.006
Apolipoprotein B mg/dl 2.17 0.99 0.14 0.95 0.99 0.32
Abbreviations are in the Appendix. x2 means the Chi-square statistic.
Table 6. Independent predictors of 2-year mortality in hemodialysis patients in the multivariate Cox regression analysis
All-cause mortality Cardiovascular mortality
Predictor Units x2 Relative risk P x2 Relative risk P
Age years 12.25 1.04 0.0005 21.42 1.11 ,0.0001
C-reative protein mg/liter 7.65 1.11 0.005 19.20 1.22 ,0.0001
BMI kg/m2 12.66 0.87 0.0004 9.77 0.85 0.001
Diabetes Ref 5 nondiabetic 5.41 1.93 0.02 10.08 3.21 0.001
Pre-existing CVD Ref 5 no CVD 5.22 1.93 0.02
Serum albumin g/liter 4.85 0.39 0.02
Gender Ref 5 male 6.44 0.37 0.01
Abbreviations are in the Appendix. Statistical parameters were established after a multivariate stepwise logistic regression process by the Cox proportional hazards
method. x2 means the Chi-square statistic.
the relatively high mean level of Salb in our cohort of although clinical signs of infections were not apparent,
and patients hospitalized for acute illness were not in-hemodialysis patients, there was a significant negative
correlation between Salb and CRP, as well as SAA. These cluded in the study. However, other recently published
studies reported an identical distribution of elevatedfindings confirm previous data indicating that low Salb in
hemodialysis patients is essentially a sign of an activated CRP concentrations in hemodialysis patients [19, 23, 24,
30]. In our study, the risk of all-cause and of cardiovascu-acute phase response [23, 24].
In accordance with other studies [25, 26], cardiovascu- lar death during follow-up increased significantly with
each increasing quartile of CRP values. Patients withlar events were the most common causes of death in this
study. Recent investigations confirmed an association baseline levels of CRP in the highest quartile compared
with patients with CRP levels in the lowest quartile ex-between acute phase indices, such as CRP and sialic acid,
and coronary heart disease in the general population [18, hibited a 4.6-fold and a 5.5-fold higher relative risk for
all-cause and for cardiovascular mortality, respectively.27]. In apparently healthy men, plasma CRP concentra-
tion was found to have a prognostic value in predicting C-reactive protein is a sensitive major acute phase
reactant in humans [31]. Its biologic action remains lesscardiovascular events during a follow-up period exceeding
eight years [18]. Furthermore, in nonrenal subjects with well defined. Because its half-life is approximately 24
hours, a shortcoming of this study might be the use ofangina, CRP and SAA levels have a prognostic value to
predict the progression to myocardial infarction [28, 29]. a single point measurement at baseline of the follow-
up period. We cannot fully exclude that hemodialysisBergstro¨m et al were the first to suggest that CRP may
predict mortality in hemodialysis patients [19]. In con- patients exhibiting marked elevated CRP levels suffer
from a clinical inapparent acute infection. Ridker et altrast to the data of nonrenal subjects, in our hemodialysis
patient population, the CRP values were much higher, have also demonstrated that a single point measurement
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of CRP predicts cardiovascular death several years in tween the size of the apo(a) isoprotein and the serum
Lp(a) concentrations. So far, all studies show elevatedadvance [18]. Our study follows the same track. How-
ever, we suppose that the correlation between activated serum Lp(a) concentration in hemodialysis patients [41].
Dieplinger et al first reported that elevated serum Lp(a)acute phase and mortality will be strengthened by using
two or more measurements of CRP over time. Patients in hemodialysis patients was due to a rise within HMW
isoforms [7]. Following renal transplantation, Lp(a) lev-whose CRP levels remain elevated over time would be
expected to have an even greater mortality than patients els decreased in those patients with HMW isoproteins
[42]. However, the specific causes for the high Lp(a)with occasionally elevated CRP levels.
Hypertriglyceridemia and decreased HDL-C are hall- concentrations remained unresolved. Lp(a) has been
shown to have the characteristics of an acute phase re-marks of plasma lipid abnormality in chronically uremic
patients. HDL-C and its structural protein component actant [9]. Kario et al demonstrated a close relationship
between high Lp(a) levels and the acute phase reaction,apo A-I were significantly lower in hemodialysis patients
with an activated acute phase response. Low serum con- as shown by correlations with CRP, sialic acid, and IL-6 in
hemodialysis patients [43]. Our data confirm that Lp(a)centrations of HDL-C are associated with increased car-
diovascular disease risk in the general population [32], reacts as an acute phase protein in hemodialysis patients.
The results further identify the acute phase response asas well as in patients with chronic renal failure [33].
Recently, Koch et al have found that low apo A-I is an the cause of the rise of Lp(a) levels in relation to the
specific isoform. Because seven IL-6–responsive elementindependent predictor of cardiac and noncardiac death
in 412 diabetic dialysis patients [12]. Abnormal catabo- sequence motifs can be identified in the 59 flanking regu-
latory region of the apo(a) gene on chromosome 6, it islism of triglyceride-rich apo B-containing lipoproteins
and HDL is caused by decreased lipoprotein lipase, he- likely that apo(a) responds as an acute phase reactant
[44]. However, it remains unclear why inflammation onlypatic triglyceride lipase, and activity of lecithin-choles-
terol acyl-transferase [1, 2]. Activity of these lipolytic has an impact on HMW isoproteins.
Apart from uremic dyslipidemia and high serum Lp(a),enzymes is inhibited by cytokines such as tumor necrosis
factor-a, interleukin (IL)-1, and IL-2 [34, 35]. These cyto- an activation of blood coagulation is suggested to be a
further mechanism responsible for progressive vascularkines are known to be major mediators of the acute
phase processes. Indeed, plasma levels and synthesis of injury in patients with ESRD [12–15]. Fibrinogen, identi-
fied as a major independent cardiovascular risk factor,these cytokines have been found to be increased in he-
modialysis patients [36, 37]. In addition, the uremic lipo- is a principal coagulation protein as well as an acute
phase reactant. Produced by hepatocytes, it is under reg-protein profile resembles several abnormalities typically
seen in patients with acute infection [16], severe trauma, ulation of cytokines, especially IL-6 [12]. Consistent with
earlier reports [14, 15] fibrinogen was found to be mark-and myocardial infarction [17, 38]. These data support
the hypothesis that an inflammatory condition may, in edly increased in our group of hemodialysis patients.
Patients with elevated CRP and SAA values showedpart, be responsible for the disturbed lipoprotein metab-
olism in chronic hemodialysis patients. Furthermore, ele- significantly higher fibrinogen levels, supporting the hy-
pothesis that an inflammatory condition partly contrib-vated concentrations of the acute phase protein SAA
were found in 47% of patients. SAA is an apolipoprotein utes to the increased fibrinogen levels in plasma of hemo-
dialysis patients. Recently, fibrinogen was identified asthat associates with HDL cholesterol, displacing apo A-I
and acting as a signal to redirect HDL cholesterol from an independent predictor of death in hemodialysis pa-
tients [12, 13]. However, these studies did not considerthe liver to the macrophage for use in repairing injured
tissue [31, 39, 40]. On the other hand, replacement of acute phase reactants. In our study, the univariate Cox
regression analysis identified fibrinogen as predictor ofapo A-I by SAA may convert HDL to a nonfunctional
or even proinflammatory particle. Sustained elevated all-cause and cardiovascular mortality. However, in the
multivariate Cox regression analysis, fibrinogen failed toconcentrations of SAA may thus be a factor in the accel-
erated atherosclerosis of hemodialysis patients. be an independent predictor of mortality.
It is not clear what activates the acute phase responseDuring recent years, substantial evidence has accumu-
lated suggesting that Lp(a) is another important risk in hemodialysis patients. Probably intermittent stimula-
tion by endotoxins originating from the dialysis waterfactor for cardiovascular disease in the general popula-
tion, as well as in dialysis patients [7]. Lp(a) is an LDL- supply and artificial vein grafts or bioincompatibility may
play a role. The latter might activate an inflammatorylike lipoprotein containing a unique apolipoprotein called
apo(a). Apo(a) exhibits an extreme size polymorphism process in chronic hemodialysis patients, but the avail-
able data are inconsistent. Although some studies foundwith the apo(a) isoproteins, ranging in size from 420 to
840 kDa. Inherited in an autosomal codominant fashion, an inflammatory response during hemodialysis with bi-
oincompatible membranes [45, 46], others did not detectthe apo(a) isoprotein is closely correlated with serum
Lp(a) concentrations, with an inverse correlation be- any differences in acute phase reactants during treatment
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